|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 167.3 USD | -0.30% |
|
+1.60% | +7.95% |
| Apr. 25 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
| Apr. 25 | AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint | MT |
AbbVie Inc.'s third-quarter revenue from its immunology portfolio was $5.79 billion, a 14.8% increase year over year. That result included revenue from AbbVie's Humira medication of $5.14 billion, a figure that rose 4.1% year over year. "AbbVie Logs 3Q Sales Growth on Higher Immunology, Oncology Results," published at 8:22 a.m. ET, incorrectly said that immunology revenue increased 4.1%, to $5.14 billion.
(END) Dow Jones Newswires
10-30-20 0950ET
| 1st Jan change | Capi. | |
|---|---|---|
| +7.95% | 297B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B | |
| +2.07% | 117B |
ABBVIE INC. 
